Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets, and potentially valuable prognostic information. Monoclonal antibody therapies, radioimmunoconjugates and other new agents such as proteosome inhibitors are providing important new treatment options for patients.

In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of patients across the complex landscape of lymphoma subtypes. Researchers and practitioners alike will welcome this useful summary of the state of the art in this field.

Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets, and potentially valuable prognostic information. Monoclonal antibody therapies, radioimmunoconjugates and other new agents such as proteosome inhibitors are providing important new treatment options for patients.

In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of patients across the complex landscape of lymphoma subtypes. Researchers and practitioners alike will welcome this useful summary of the state of the art in this field.

Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets, and potentially valuable prognostic information. Monoclonal antibody therapies, radioimmunoconjugates and other new agents such as proteosome inhibitors are providing important new treatment options for patients.

In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of patients across the complex landscape of lymphoma subtypes. Researchers and practitioners alike will welcome this useful summary of the state of the art in this field.